Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.4.0.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues    
Net Revenues $ 1,878,813 $ 13,648,782
Operating expenses:    
Direct costs of revenue 564,200 4,031,274
General and administrative 5,954,046 5,639,933
Sales and marketing expenses 873,440 1,182,221
Engineering 522,768 0
Bad debt 1,285 0
Depreciation and amortization 727,270 580,793
Total operating expenses 8,643,009 11,434,221
Income (Loss) from operations (6,764,196) 2,214,561
Other income (expense):    
Other income 100,010 21
Unrealized gain (loss) on derivative instruments 3,433,588 0
Gain (Loss) on legal settlement 0 275,028
Interest expense (1,013,413) (505,101)
Total other income (expense) 2,520,185 (230,052)
Income (Loss) before income taxes (4,244,011) 1,984,509
Provision for income taxes 0 977,500
Net income (loss) attributable to Rennova Health (4,244,011) 1,007,009
Preferred stock dividends 0 523,050
Net income (loss) attributable to Rennova Health common shareholders $ (4,244,011) $ 483,959
Net income (loss) per common share: Basic $ (.29) $ .04
Net income (loss) per common share: Diluted $ (0.29) $ 0.04
Weighted average number of shares outstanding during the period - Basic 14,816,586 11,937,530
Weighted average number of shares outstanding during the period - Diluted 14,816,586 12,809,335